NCT04857840View on ClinicalTrials.gov

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

PHASE3TerminatedINTERVENTIONAL

Enrollment

419

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions

Hypertension (HTN)

Interventions

DRUG

Firibastat (QGC001) Period 1

1000 mg (2 x 500 mg) tablets QD per Os

Trial Locations (2)

20110

Manassas Clinical Research Center, Manassas

M3J 0K2

Canadian Phase Onward, Toronto

Sponsors

Collaborators (1)

PRA Health Sciences

All Listed Sponsors

collaborator

PRA Health Sciences

INDUSTRY

lead

Quantum Genomics SA

INDUSTRY

NCT04857840 - Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) | Biotech Hunter | Biotech Hunter